의약품 시험용 실험실 오가노이드 시장 규모, 점유율 및 성장 분석 : 오가노이드 유형별, 용도별, 약제 유형별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Lab-Grown Organoids For Drug Testing Market size was valued at USD 1.2 Billion in 2024 and is poised to grow from USD 1.34 Billion in 2025 to USD 3.2 Billion by 2033, growing at a CAGR of 11.5% during the forecast period (2026-2033).

The Global Lab-Grown Organoids market for drug testing showcases three-dimensional cellular constructs that mimic organ functions, allowing pharmaceutical companies to evaluate drug efficacy and toxicity without animal testing. The shift towards these innovative in-vitro systems is largely driven by increasing regulatory demands for data and the high costs associated with clinical trial failures. As pharmaceutical companies move toward personalized medicine, patient-specific organoids derived from induced pluripotent stem cells offer a unique platform for observing drug responses accurately. This shift reduces attrition rates in drug development, as demonstrated by collaborations identifying issues like hepatotoxicity early in trials. Consequently, there is a growing investment in automation and bioprinting technologies, opening up new avenues for suppliers to provide organoid kits and data analytics services.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lab-Grown Organoids For Drug Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lab-Grown Organoids For Drug Testing Market Segments Analysis

Global lab-grown organoids for drug testing market is segmented by organoid type, application, drug type, end user and region. Based on organoid type, the market is segmented into Liver Organoids, Intestinal Organoids, Brain Organoids, Kidney Organoids, Lung Organoids, Tumor Organoids and Others. Based on application, the market is segmented into Drug Screening, Drug Toxicity Testing, Drug Efficacy Testing, Personalized Medicine and Others. Based on drug type, the market is segmented into Small-Molecule Drugs, Biologics, Gene & Cell Therapies and Others. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic & Research Institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lab-Grown Organoids For Drug Testing Market

The increasing focus on human-relevant models is propelling the demand for lab-grown organoids in drug testing, as these advanced systems enhance the predictive accuracy of preclinical studies. This shift aims to minimize late-stage drug failures and their associated costs, making drug development more efficient. Researchers have discovered that lab-grown organoids effectively mimic essential physiological functions, facilitating a more dependable evaluation of drug efficacy and toxicity. As pharmaceutical companies embrace these innovative platforms, the need for organoid systems, supporting reagents, and specialized services is surging, driving substantial growth across various therapeutic sectors worldwide.

Restraints in the Global Lab-Grown Organoids For Drug Testing Market

The Global Lab-Grown Organoids for Drug Testing market faces significant challenges due to the high costs associated with their manufacturing. Producing lab-grown organoids demands specialized bioreactors, high-purity media, and a skilled workforce, which collectively increase the cost per unit. This financial barrier restricts access for smaller biotech companies and academic institutions operating on limited budgets, thereby hindering widespread market adoption. Furthermore, the necessity for stringent quality control and extensive validation processes imposes additional financial and operational strain. As a result, many organizations may continue to rely on traditional animal models for early-stage screening, delaying the integration of organoids into drug development workflows.

Market Trends of the Global Lab-Grown Organoids For Drug Testing Market

The Global Lab-Grown Organoids for Drug Testing market is witnessing a notable trend towards personalized medicine, as pharmaceutical companies adopt patient-derived organoids for early-stage screening. This innovative approach facilitates therapy customization based on individual genetic profiles, enhancing precision in efficacy evaluations while mitigating late-stage trial failures. The drive towards precision oncology and treatments for rare diseases is pushing the creation of collaborative platforms that merge organoid biobanks with clinical data. These initiatives promote agile candidate molecule development and deepen collaborations between biotech companies and academic institutions, leveraging integrated bioinformatics to refine data interpretation and expedite decision-making processes across various research sites.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porter's Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitutes
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Lab-Grown Organoids for Drug Testing Market Size by Organoid Type & CAGR (2026-2033)

• Market Overview
• Liver Organoids
• Intestinal Organoids
• Brain Organoids
• Kidney Organoids
• Lung Organoids
• Tumor Organoids
• Others

Global Lab-Grown Organoids for Drug Testing Market Size by Application & CAGR (2026-2033)

• Market Overview
• Drug Screening
• Drug Toxicity Testing
• Drug Efficacy Testing
• Personalized Medicine
• Others

Global Lab-Grown Organoids for Drug Testing Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Small-Molecule Drugs
• Biologics
• Gene & Cell Therapies
• Others

Global Lab-Grown Organoids for Drug Testing Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions
• Others

Global Lab-Grown Organoids for Drug Testing Market Size & CAGR (2026-2033)

• North America (Organoid Type, Application, Drug Type, End User)
  • US
  • Canada
• Europe (Organoid Type, Application, Drug Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Organoid Type, Application, Drug Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Organoid Type, Application, Drug Type, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Organoid Type, Application, Drug Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• STEMCELL Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HUB Organoids
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crown Bioscience International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InSphero AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emulate, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mimetas B.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corning Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HUB Organoids B.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DefiniGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TissUse GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nortis Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CN Bio Innovations Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biopredic International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organovo Holdings, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations